Journal
CANCER SCIENCE
Volume 106, Issue 5, Pages 512-521Publisher
WILEY-BLACKWELL
DOI: 10.1111/cas.12631
Keywords
Bispecific antibodies; immunotherapy; multiple myeloma; natural killer cells; T cells
Categories
Funding
- Priority Academic Program Development of Jiangsu Higher Education Institutions
- National Natural Science Foundation of China
- Science and Technology Support Program Project of Jiangsu Province
- Finance Department of Jiangsu Province, China
- Education Department of Jiangsu Province, China
- National Natural Science Foundation Committee (China)
- Science & Technology Department of Jiangsu Province, China
Ask authors/readers for more resources
Bispecific antibodies play an important role in immunotherapy. They have received intense interest from pharmaceutical enterprises. The first antibody drug, OKT3 (muromonab-CD3), showed great performance in clinical treatment. We have successfully developed a single-chain variable fragment (ScFv) combination of anti-CD3 ScFv and anti-CD138 ScFv with the hIgG1 Fc (hIgFc) sequence. The novel bispecific T-cell engager (BiTE) with an additional hIgFc (BiTE-hIgFc, STL001) can target T cells, natural killer cells, and multiple myeloma cells (RPMI-8226 or U266). In addition, BiTE-hIgFc (STL001) has nanomolar-level affinity to recombinant human CD138 protein and shows more potent antitumor activity against RPMI-8226 cells than that of separate aCD3-ScFv-hIgFc and aCD138-ScFv-hIgFc, or the isotype mAb invitro or invivo.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
